Document Type: Original Research
Junior Resident, M.B.B.S, Dept. of Pathology, Pt. BD Sharma, PGIMS Rohtak, Haryana, India
Professor, M.B.B.S, M.D, Dept. of Pathology, Pt BD Sharma, PGIMS Rohtak, Haryana, India
Senior Resident, M.B.B.S, M.D, DNB, Dept. Of Pathology, Pt BD Shrama, PGIMS Rohtak, Haryana, India
Professor & Head, M.B.B.S, M.S, M.Ch. Dept. of Urology, Pt. BD Sharma, PGIMS Rohtak, Haryana, India
Professor & Head, M.B.B.S, M.D, Dept. of Pathology, Pt BD Sharma, PGIMS Rohtak, Haryana, India
Background and Objective: Adenocarcinoma of the prostate is the second most common cause of cancer. The loss of CD10 is a common early event in human prostate cancer and is seen in lower Gleason Score malignancies while increased and altered expression is seen in high Gleason Score tumors, lymph nodes and bone metastasis.
Material and Methods: This was a prospective observational study conducted on 75 patients suspected to have prostate cancer. Immunohistochemical profile was assessed for PSA, AMACR and CD10 immunostaining. The intensity of CD10 expression and pattern of CD10 staining of tumor cells was evaluated.
Results: The patients were in age group of 50-90 years with a mean age of 70.97 ± 9.51 years. As the Grade Group/Gleason Score increased, the number of cases showing negative expression decreased and the pattern of expression changed from membranous to cytoplasmic to both types of expression. As the serum PSA levels increased the intensity of expression changed from focally positive to diffusely positive. The pattern of expression also changed from membranous to cytoplasmic to both (membranous + cytoplasmic) types of expression with an increase in PSA levels.
Conclusion: By immunohistochemical analysis we can identify CD10 positive tumors, which may warrant more aggressive initial therapy. A number of drugs against CD10 are available based on which potential targeted therapies could be formulated.